8-K: Bionano Genomics Reports Q3 2024 Results: Revenue Declines Amidst Restructuring Efforts

Bionano Genomics reported a 35% decrease in revenue for Q3 2024 compared to the same period last year, alongside a reduction in cash burn due to restructuring.

Summary

• Bionano Genomics announced its financial results for the third quarter of 2024, showing a total revenue of $6.1 million, which is a 35% decrease compared to Q3 2023.
• The revenue included $6.6 million in core product and software sales, offset by a $0.5 million write-down of aged receivables from discontinued clinical service products.
• The company's installed base of optical genome mapping (OGM) systems reached 368, a 22% increase year-over-year.
• Flowcell sales increased by 27% year-over-year, with 7,835 nanochannel array flowcells sold in Q3 2024.
• GAAP gross margin was (139)%, while non-GAAP gross margin was 26%.
• GAAP operating expenses were $35.5 million, and non-GAAP operating expenses were $16.1 million, representing a decrease of 69% and 49% respectively, compared to Q3 2023.
• The company's cash, cash equivalents, available-for-sale securities, and restricted cash totaled $23.4 million as of September 30, 2024.
• Bionano raised approximately $0.1 million from ATM sales during the third quarter and an additional $1.2 million after the quarter ended.
• The company also announced a registered direct offering and concurrent private placement of warrants, raising $10 million upfront with potential for an additional $26 million upon exercise of warrants.
• A special shareholder meeting was adjourned due to a lack of quorum and will reconvene on November 27, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue decline and negative gross margins, offset by cost-cutting measures and potential future funding. The overall sentiment is cautiously negative due to the financial challenges, but there are some positive developments in technology adoption and cost control.

Positives

• The installed base of OGM systems grew by 22% year-over-year, indicating continued adoption of the technology.
• Flowcell sales increased by 27% year-over-year, suggesting increased utilization of existing systems.
• Non-GAAP operating expenses decreased by 49% year-over-year, reflecting the success of cost-cutting measures.
• The company secured $10 million in upfront funding through a registered direct offering and concurrent private placement of warrants, with potential for an additional $26 million.
• A multi-site study demonstrated the clinical utility of OGM in multiple myeloma, potentially leading to better treatment decisions.
• Cash burn was significantly lower than the prior year period, indicating improved financial discipline.

Negatives

• Total revenue decreased by 35% compared to the same quarter last year, indicating a significant decline in sales.
• GAAP gross margin was a negative (139)%, primarily due to a write-down of aged receivables and impairment charges.
• The company experienced a $0.5 million write-down of aged receivables from discontinued clinical service products.
• The special shareholder meeting was adjourned due to a lack of quorum, indicating potential challenges in securing shareholder support.
• The company's cash position is $23.4 million, with $11.4 million subject to restrictions, which may limit financial flexibility.

Risks

• The company's ability to continue as a going concern is dependent on managing costs and obtaining significant additional financing.
• There are risks associated with the timing and amount of revenue recognition.
• Adverse geopolitical and macroeconomic events could impact the business and the global economy.
• The company faces challenges in developing, manufacturing, and commercializing products.
• There is a risk that the company may not be able to cure deficiencies in compliance with Nasdaq Listing Rules.
• The company's ability to obtain stockholder approval for the exercise of warrants is not guaranteed.
• Study results may differ or contradict the results mentioned in the press release.

Future Outlook

The company expects to see a reduction in non-cash charges in the future and is focused on extending its cash runway. They are also preparing for new opportunities and are working to secure revenue and growth from their installed base of customers.

Management Comments

• Erik Holmlin, PhD, president and chief executive officer of Bionano, stated that the results reflect improving momentum for OGM utilization and flowcell sales, despite overall revenues being below expectations.
• He also noted that cash burn for the quarter was significantly lower than the prior year period due to the company's reorganization plan.
• Holmlin mentioned that the company's disciplined approach to mitigating operational expenses and cash burn has been painful but necessary.

Industry Context

The announcement comes as the genomics industry continues to evolve, with increasing focus on advanced technologies like optical genome mapping. Bionano is positioning itself to capitalize on the growing demand for more comprehensive genomic analysis, particularly in areas like cancer research and diagnostics. The company's focus on cost reduction and revenue generation from its installed base reflects a broader trend in the industry towards sustainable growth.

Comparison to Industry Standards

• Bionano's revenue decline of 35% is concerning when compared to other genomics companies that have shown growth in the same period, such as Illumina, which has reported modest growth in recent quarters.
• The negative GAAP gross margin of (139)% is significantly below industry standards, where most companies aim for a gross margin of 50% or higher. Companies like Pacific Biosciences typically report gross margins in the 30-40% range, even with similar capital equipment sales.
• The 22% growth in installed base is positive but needs to translate into higher revenue per system to be sustainable. Companies like 10x Genomics have demonstrated the ability to drive significant revenue from consumables after initial system sales.
• The reduction in operating expenses is a positive step, but the company needs to demonstrate that it can achieve profitability without sacrificing growth. Companies like Exact Sciences have shown that it is possible to achieve both cost control and revenue growth.
• The successful implementation of the CPT code is a positive development, but the company needs to demonstrate that it can drive adoption and reimbursement for OGM testing. Companies like Guardant Health have shown the importance of securing reimbursement for their tests.

Stakeholder Impact

• Shareholders may be concerned about the significant revenue decline and negative gross margins.
• Employees may be affected by the ongoing restructuring and cost-cutting measures.
• Customers may benefit from the increased adoption of OGM technology.
• Suppliers may be impacted by the company's financial challenges.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to reconvene the special shareholder meeting on November 27, 2024.
• The company will continue to focus on driving adoption of OGM and its technology solutions.
• The company will work to secure reimbursement for OGM testing.
• The company will continue to manage costs and seek additional financing.

Key Dates

Keywords

Optical Genome Mapping, OGM, Genomics, Flowcells, Cytogenetics, Bionano Genomics, Financial Results, Revenue, Gross Margin, Operating Expenses, Warrants, Multiple Myeloma, Hematological Malignancies